Glox Therapeutics, founded in 2023, is positioned at the cutting edge of the Biotechnology industry, focusing on pioneering precision antibiotic therapies using naturally occurring bacteriocins. With a compelling mission encapsulated in their slogan—Innovating the future of precision antibiotics with naturally occurring bacteriocin therapies—the company aims to address the growing global challenge of antibiotic resistance with targeted solutions.
Recently, Glox Therapeutics secured a substantial £4.30M Seed Round investment on 14 November 2023. This capital infusion was led by notable investors, including Scottish Enterprise and the Boehringer Ingelheim Venture Fund. The company's innovative approach and successful fundraising highlight its potential as a disruptor in the antibiotic market. Without a specific headquarter listed, their operations appear flexible, poised to adapt rapidly to emerging opportunities and challenges in the biotechnology sector.
